How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,897 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Outcomes of Unilateral Total Hip Arthroplasty in Patients Aged Under 35 Years in Iranian Population: A Preliminary Study (PubMed)

Outcomes of Unilateral Total Hip Arthroplasty in Patients Aged Under 35 Years in Iranian Population: A Preliminary Study The purpose of this study is to report outcomes of total hip arthroplasty (THA) in patients under the age of 35 years regarding pain and joint function.This preliminary analytic-descriptive study was performed in prospective consecutive series of forty-three patients younger than 35 years old who had undergone unilateral THA during a 36-month period. As the primary outcome (...) , the severity of pain using visual analog scale (VAS) of 1-10, and as the secondary outcomes, joint range of motion (ROM) and the Harris Hip Score (HHS) were assessed in the preoperative visit, 1, 6, and 18 months after operation for each patient. Complications were recorded at 6 months and 18 months after surgery.The data of VAS showed the mean severity of pain was significant between preoperation measurements and postoperative assessments (P < 0.001). The means of HHS and hip ROM were also statistically

Full Text available with Trip Pro

2018 Advanced biomedical research

62. Heart Disease Death Rates Among Blacks and Whites Aged ≥35 Years — United States, 1968–2015 (PubMed)

Heart Disease Death Rates Among Blacks and Whites Aged ≥35 Years — United States, 1968–2015 Heart disease is the leading cause of death in the United States. In 2015, heart disease accounted for approximately 630,000 deaths, representing one in four deaths in the United States. Although heart disease death rates decreased 68% for the total population from 1968 to 2015, marked disparities in decreases exist by race and state.1968-2015.The National Vital Statistics System (NVSS) data (...) on deaths in the United States were abstracted for heart disease using diagnosis codes from the eighth, ninth, and tenth revisions of the International Classification of Diseases (ICD-8, ICD-9, and ICD-10) for 1968-2015. Population estimates were obtained from NVSS files. National and state-specific heart disease death rates for the total population and by race for adults aged ≥35 years were calculated for 1968-2015. National and state-specific black-white heart disease mortality ratios also were

Full Text available with Trip Pro

2018 MMWR Surveillance Summaries

63. Pre-selection of primary intubation technique is associated with a low incidence of difficult intubation in patients with a BMI of 35 kg/m2 or higher (PubMed)

or higher.Data from 546 patients with a BMI of 35 kg/m2 or higher who underwent bariatric surgery at Wolfson Medical Center from 2010 through 2014 was retrospectively extracted and analyzed for demographics, predictors of DI and intubation techniques employed. Difficult intubation was defined as the presence of at least one of the followings: laryngoscopy grade 3 or 4, need for >1 laryngoscopy or intubation attempt, need for changing the blade size, failed direct laryngoscopy (DL), difficult or failed (...) Pre-selection of primary intubation technique is associated with a low incidence of difficult intubation in patients with a BMI of 35 kg/m2 or higher The incidence of difficult intubation (DI) in obese patients may reach a two-digit figure. No studies have assessed the effect of primary use of special intubation devices on lowering the incidence of DI. We assessed the effect of primary selection of special intubation techniques on the incidence of DI in patients with a BMI of 35 kg/m2

Full Text available with Trip Pro

2018 Romanian Journal of Anaesthesia and Intensive Care

64. Correction for Johnson et al., “Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species” (PubMed)

Correction for Johnson et al., “Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species” 29348328 2018 01 30 2169-8287 6 3 2018 Jan 18 Genome announcements Genome Announc Correction for Johnson et al., "Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species". e01144-17 10.1128/genomeA.01144-17 Johnson Shannon L SL http://orcid.org/0000-0002-3972-9208 Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA shannonj@lanl.gov. Daligault (...) Genome Announc 101595808 Genome Announc. 2015 Apr 30;3(2): 25931591 2018 1 20 6 0 2018 1 20 6 0 2018 1 20 6 0 epublish 29348328 6/3/e01144-17 10.1128/genomeA.01144-17 PMC5773713

Full Text available with Trip Pro

2018 Genome Announcements

65. Nanostructural Differentiation and Toxicity of Amyloid-β25-35 Aggregates Ensue from Distinct Secondary Conformation (PubMed)

. In this work, Aβ25-35, a fragment of amyloid β(1-42) (Aβ42), was selected to investigate the correlation between secondary structures and toxicity of amyloid fibrils. Furthermore, each aggregation assemblies show different cell membrane disruption and cytotoxicity. The structural analysis of amyloid aggregates originated from different secondary structure motifs is helpful to understand the mechanism of peptides/cell interactions in the pathogenesis of amyloid diseases. (...) Nanostructural Differentiation and Toxicity of Amyloid-β25-35 Aggregates Ensue from Distinct Secondary Conformation Amyloid nanostructures are originated from protein misfolding and aberrant aggregation, which is associated with the pathogenesis of many types of degenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease. The secondary conformation of peptides is of a fundamental importance for aggregation and toxicity of amyloid peptides

Full Text available with Trip Pro

2018 Scientific reports

66. Genotype–phenotype investigation of 35 patients from 11 unrelated families with camptodactyly–arthropathy–coxa vara–pericarditis (CACP) syndrome (PubMed)

Genotype–phenotype investigation of 35 patients from 11 unrelated families with camptodactyly–arthropathy–coxa vara–pericarditis (CACP) syndrome The camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is a rare autosomal recessive condition characterized by camptodactyly, noninflammatory arthropathy, coxa vara, and pericarditis. CACP is caused by mutations in the proteoglycan 4 (PRG4) gene, which encodes a lubricating glycoprotein present in the synovial fluid (...) and at the surface of articular cartilage.In the present study, we compared the clinical and molecular findings of CACP syndrome in 35 patients from 11 unrelated families. In 28 patients, whole exome sequencing was used to investigate genomic variations.We found that camptodactyly of hands was the first symptom presented by most patients. Swelling of wrists, knees, and elbows began before 4 years of age, while the age of joint involvement was variable. Patients reported an increased pain level after the age

Full Text available with Trip Pro

2018 Molecular Genetics & Genomic Medicine

67. Comparison of the anti-apoptotic effects of 15- and 35-minute suspended moxibustion after focal cerebral ischemia/reperfusion injury (PubMed)

Comparison of the anti-apoptotic effects of 15- and 35-minute suspended moxibustion after focal cerebral ischemia/reperfusion injury Heat-sensitive suspended moxibustion has a neuroprotective effect against focal cerebral ischemia/reperfusion injury, but the underlying mechanisms remain unclear. The duration of heat-sensitive suspended moxibustion (usually from 30 minutes to 1 hour) is longer than traditional suspended moxibustion (usually 15 minutes). However, the effects of 15- and 35-minute (...) suspended moxibustion in rats with cerebral ischemia/reperfusion injury are poorly understood. In this study, we performed 15- or 35-minute suspended moxibustion at acupoint Dazhui (GV14) in an adult rat model of focal cerebral ischemia/reperfusion injury. Infarct volume was evaluated with the 2,3,5-triphenyltetrazolium chloride assay. Histopathological changes and neuronal apoptosis at the injury site were assessed by hematoxylin-eosin staining and terminal deoxynucleotidyl transferase dUTP nick end

Full Text available with Trip Pro

2018 Neural Regeneration Research

68. Diagnostic yield of electromagnetic navigational bronchoscopy: results of initial 35 cases in a Japanese institute (PubMed)

included 35 consecutive patients who underwent ENB with superDimensionTM (Medtronic, MN, USA) for the diagnosis of pulmonary lesions from February 2016 to May 2017 in Kyoto University Hospital. The size of the target lesion varied from 8 to 25 mm (median, 15.28±5.48 mm). All ENB procedures were performed under conscious sedation using 2 to 10 mg midazolam and 1 to 10 mg morphine hydrochloride. No fluoroscopic guide was employed except in three cases.A total of 25 patients were diagnosed via ENB (...) Diagnostic yield of electromagnetic navigational bronchoscopy: results of initial 35 cases in a Japanese institute Electromagnetic navigational bronchoscopy (ENB) is a new bronchoscopic technique for navigational transbronchial lung biopsy (TBLB) that guides the sheath to the target lesion in real time. Herein, we report our experience with this navigational system, its diagnostic yields, and associated complications.A single-center, single-operator retrospective chart review was performed. We

Full Text available with Trip Pro

2018 Journal of thoracic disease

69. Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD. Condition or disease Intervention/treatment Phase Alzheimer Disease, Early Onset Drug: AD-35 60mg group Drug: AD-35 90mg group Drug: Placebo group Phase 2 Detailed Description: Approximately 88 subjects are planned to be enrolled for the entire study. Initially, approximately 30 subjects will be randomized via a centralized interactive response technology (IRT) in a 1:2 ratio (ie, approximately 10 (...) subjects will be enrolled and will be randomized in a 1:1:3 ratio to receive placebo, 60 mg AD-35, and 90 mg AD-35, respectively.After the first 6 months of double-blind treatment, subjects on active study drug will remain on the current dose, and subjects assigned to placebo will receive 60 mg and 90 mg AD-35 in a 1:2 ratio, respectively, for an additional 6 months of open-label treatment. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated

2018 Clinical Trials

70. Behavioral Effects of Drugs: Inpatient (35)

Behavioral Effects of Drugs: Inpatient (35) Behavioral Effects of Drugs: Inpatient (35) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Behavioral Effects of Drugs: Inpatient (35) (BED IN 35) The safety (...) provided by (Responsible Party): Craig Rush, University of Kentucky Study Details Study Description Go to Brief Summary: This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological effects of cocaine. Condition or disease Intervention/treatment Phase Cocaine Use Disorder Drug: Cocaine Drug: Placebo oral capsule Drug: Methylphenidate Early Phase 1 Study Design Go to Layout table for study

2018 Clinical Trials

71. Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

seronegative women 16 to 35 years of age. Participants will receive blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and will be followed to approximately Month 36. The primary hypothesis of the study is that administration of a 3-dose regimen of V160 will reduce the incidence of primary CMV infection compared to placebo. Condition or disease Intervention/treatment Phase (...) : 16 Years to 35 Years (Child, Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy based on medical history and physical examination Serologically confirmed to be CMV seronegative Have direct exposure to young children (≤5 years of age) at home or occupationally Of child bearing potential Agrees to avoid becoming pregnant during the 6-month treatment period and for at least 4 weeks after the last dose of study drug by either 1) practicing

2018 Clinical Trials

72. Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward

Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward (VELOCITE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating

2018 Clinical Trials

73. Magnetic Nanoparticle Sperm Separation for Teratozoospermia Male and Women Older Than 35 Years

Assignment Masking: Triple (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Other Official Title: Magnetic Nanoparticle Sperm Separation for ICSI Cycles With Teratozoospermia and Over 35 Years Old Women Age Actual Study Start Date : September 17, 2018 Estimated Primary Completion Date : September 20, 2019 Estimated Study Completion Date : October 1, 2019 Arms and Interventions Go to Arm Intervention/treatment Experimental: Magnetic nanoparticle selection for teratozoospermia Other: Sperm (...) Magnetic Nanoparticle Sperm Separation for Teratozoospermia Male and Women Older Than 35 Years Magnetic Nanoparticle Sperm Separation for Teratozoospermia Male and Women Older Than 35 Years - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

74. Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Kenyan Children 6-35 Months

) and the study statistician can be blinded to the group assignment Primary Purpose: Prevention Official Title: Programme Effectiveness of an Integrated Programme to Reduce Maternal and Child Malnutrition in Kenya: Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Children 6-35 Months of Age at Recruitment Actual Study Start Date : March 12, 2018 Estimated Primary Completion Date : July 1, 2020 Estimated Study Completion Date : July 1, 2020 Arms and Interventions Go to Arm (...) Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Kenyan Children 6-35 Months Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Kenyan Children 6-35 Months - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

75. Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio. Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment. Total of three or five visits are scheduled depeding on dosing schedule (...) the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 6 Months to 35 Months (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Children aged 6 to 35 months Those who were normal gestational age at birth (for children aged 6 months to <1 year) Those who have provided written informed consent to study participation and compliance with study instructions after

2018 Clinical Trials

76. Sex Differences in the Temporal Recovery of Neuromuscular Function Following Resistance Training in Resistance Trained Men and Women 18 to 35 Years (PubMed)

Sex Differences in the Temporal Recovery of Neuromuscular Function Following Resistance Training in Resistance Trained Men and Women 18 to 35 Years To investigate sex differences in the temporal recovery of neuromuscular function following resistance training (RT), eleven men and eight women 18-35 years completed a single RT bout (barbell back-squats, 80 % 1RM, 5 sets × 5 reps, 25 % duty cycle, then 1 set × max reps). Measures of muscle function (isometric, concentric, eccentric knee extensor (...) strength, and countermovement jump (CMJ) height), serum creatine kinase activity (CK) and lower-body muscle pain were assessed before RT (0 h), +4 h, +24 h, +48 h, and +72 h post-RT. Data are mean % change from PRE (SD) and effect size (ω2, d). Men and women had similar RT-experience (men, 2.1 (0.8) years vs. women 2.4 (1.0) years, P = 0.746, and d = 0.3) and 1RM strength per kg lean mass (men, 1.9 (0.2) kg⋅kg-1 vs. women, 1.8 (0.3) kg⋅kg-1, P = 0.303, and d = 0.3). A 36 (12)% increase in lower-body

Full Text available with Trip Pro

2018 Frontiers in physiology

77. Association between availability of children’s book and the literacy-numeracy skills of children aged 36 to 59 months: secondary analysis of the UNICEF Multiple-Indicator Cluster Surveys covering 35 countries (PubMed)

is beneficial at large scale in low and middle-income settings.We conducted a secondary analysis using data from the multiple-indicator cluster survey, covering 100 012 children aged 36-59 months, from 35 countries. The outcome was children being on-track for a literacy-numeracy index (LNI) constructed from three questions assessing children's ability to identify/name at least 10 letters of the alphabet, read at least four simple popular words and know the names and symbols of all numbers from 1-10 (...) Association between availability of children’s book and the literacy-numeracy skills of children aged 36 to 59 months: secondary analysis of the UNICEF Multiple-Indicator Cluster Surveys covering 35 countries Stimulating home environments that have children's books, pictures and play toys facilitate caregiver-child interactions and enhance children's development. Although this has been demonstrated in small-scale intervention studies, it is important to document whether book ownership

Full Text available with Trip Pro

2018 Journal of global health

78. Membrane-Modulating Drugs can Affect the Size of Amyloid-β25–35 Aggregates in Anionic Membranes (PubMed)

Membrane-Modulating Drugs can Affect the Size of Amyloid-β25–35 Aggregates in Anionic Membranes The formation of amyloid-β plaques is one of the hallmarks of Alzheimer's disease. The presence of an amphiphatic cell membrane can accelerate the formation of amyloid-β aggregates, making it a potential druggable target to delay the progression of Alzheimer's disease. We have prepared unsaturated anionic membranes made of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dimyristoyl (...) -sn-glycero-3-phospho-L-serine (DMPS) and added the trans-membrane segment Aβ25-35. Peptide plaques spontaneously form in these membranes at high peptide concentrations of 20 mol%, which show the characteristic cross-β motif (concentrations are relative to the number of membrane lipids and indicate the peptide-to-lipid ratio). We used atomic force microscopy, fluorescence microscopy, x-ray microscopy, x-ray diffraction, UV-vis spectroscopy and Molecular Dynamics (MD) simulations to study three

Full Text available with Trip Pro

2018 Scientific reports

79. C. elegans RAB-35: Dual roles in apoptotic cell clearance (PubMed)

C. elegans RAB-35: Dual roles in apoptotic cell clearance 30138327 2018 12 17 2018 12 17 1553-7404 14 8 2018 08 PLoS genetics PLoS Genet. C. elegans RAB-35: Dual roles in apoptotic cell clearance. e1007534 10.1371/journal.pgen.1007534 Rocheleau Christian E CE 0000-0001-6738-5636 Division of Endocrinology and Metabolism, Department of Medicine, McGill University, Montreal, Quebec, Canada. Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada. Program in Metabolic (...) .1007534 PGENETICS-D-18-01227 PMC6107104 Mol Cell Biol. 2010 Mar;30(6):1421-33 20065041 Nature. 2010 Apr 1;464(7289):778-82 20305638 Dev Cell. 2006 Jun;10(6):743-57 16740477 Nat Rev Immunol. 2014 Mar;14(3):166-80 24481336 Small GTPases. 2010 Nov;1(3):170-173 21686272 Nat Cell Biol. 2008 May;10(5):556-66 18425118 Cell Death Differ. 2014 Jun;21(6):845-53 24632947 PLoS Biol. 2008 Mar 18;6(3):e61 18351800 Nat Cell Biol. 2011 Jun 26;13(8):981-8 21706022 Science. 2009 Sep 4;325(5945):1250-4 19729655 Cell Mol

Full Text available with Trip Pro

2018 PLoS genetics

80. The small GTPase RAB-35 defines a third pathway that is required for the recognition and degradation of apoptotic cells (PubMed)

further identified TBC-10 as a putative GTPase-activating protein (GAP), and FLCN-1 and RME-4 as two putative Guanine Nucleotide Exchange Factors (GEFs), for RAB-35. We found that RAB-35 was required for the efficient incorporation of early endosomes to phagosomes and for the timely degradation of apoptotic cell corpses. More specifically, RAB-35 promotes two essential events that initiate phagosome maturation: the switch of phagosomal membrane phosphatidylinositol species from PtdIns(4,5)P2 to PtdIns (...) (3)P, and the recruitment of the small GTPase RAB-5 to phagosomal surfaces. These functions of RAB-35 were previously unknown. Remarkably, although the phagocytic receptor CED-1 regulates these same events, RAB-35 and CED-1 appear to function independently. Upstream of degradation, RAB-35 also facilitates the recognition of apoptotic cells independently of the known CED-1 and CED-5 pathways. RAB-35 localizes to extending pseudopods and is further enriched on nascent phagosomes, consistent

Full Text available with Trip Pro

2018 PLoS genetics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>